Increased MDK expression in non-small cell lung cancer (NSCLC) is related with malignant traits and influences breast cancer progression through the NF-κB-NR3C1 pathway, also protecting cancer cells from cannabinoid and doxorubicin treatments. Here, MDK is linked to breast carcinoma.